Kai Sutterby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai Sutterby has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Recio-Boiles
Department of Medicine, Hematology and Medical Oncology, The University of Arizona Comprehensive Cancer Center, Tucson, Arizona
19 shared publications - Alex Farrell
Caris Life Sciences Phoenix Arizona USA
19 shared publications - Amber N. Clements
Cancer Biology Graduate Program, University of Arizona, Tucson, Arizona
19 shared publications - Andrea L. Casillas
Cancer Biology Graduate Program, University of Arizona, Tucson, Arizona
19 shared publications - Anne E. Cress
The University of Arizona Comprehensive Cancer Center, Tucson, Arizona; Department of Cellular and Molecular Medicine, College of Medicine, University of Arizona, Tucson, Arizona
19 shared publications - Caitlyn E. Flores
Cancer Biology Graduate Program, University of Arizona, Tucson, AZ, USA
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy